← Human Trials & Peer-Reviewed Studies
Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study.
Plain-language guide to PMID 25876453 (2015): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 25876453
- Journal
- The lancet. Diabetes & endocrinology
- Year
- 2015
- Study type
- Observational Study
- Authors
- Mo D et al. (7 authors)
- DOI
- 10.1016/S2213-8587(15)00098-4
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.
To their knowledge, no controlled studies of the effects of long-term growth hormone replacement on fracture risk in adult patients with growth hormone deficiency exist.
The researchers assessed the effect of growth hormone treatment on fracture risk in patients with growth hormone deficiency from the international Hypopituitary Control and Complications Study (HypoCCS) surveillance database.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
In this prospective cohort study, patients with growth hormone deficiency were analysed from the HypoCCS database of adults with hypopituitarism from the USA, Canada, Japan, and 14 European countries.
Patients were eligible if they were aged 18 years or older and had an established diagnosis of growth hormone deficiency, either alone or with multiple pituitary hormone deficiencies, as identified by clinical history and biochemical testing.
How the Study Was Run
Patients were assessed over a mean follow-up period of 4·6 years (SD 3·8).
What Was Measured
The researchers assessed the effect of growth hormone treatment on fracture risk in patients with growth hormone deficiency from the international Hypopituitary Control and Complications Study (HypoCCS) surveillance database.
PubMed files the paper under topics including Fractures, Bone, Hormone Replacement Therapy, Human Growth Hormone, Incidence and Risk Factors.
What This Means in Plain Language
This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (The lancet. Diabetes & endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.